1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

19 Jun 2025
Admin
News Article

BioAegis Therapeutics Secures FDA Fast Track Designation for Lead ARDS Therapy

Overview

BioAegis Therapeutics has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead candidate, recombinant human plasma gelsolin (rhu-pGSN), aimed at treating acute respiratory distress syndrome (ARDS).

About the respiratory condition: ARDS

• ARDS is a critical respiratory condition characterised by severe lung inflammation and fluid build-up, often requiring intensive care.

• It affects over 500,000 individuals annually in the United States alone and accounts for around 10% of all ICU admissions.

• Despite its high mortality rate—estimated at 40%—there are currently no approved pharmacological treatments for the condition, highlighting a significant unmet medical need.

Post FDA approval

• The designation is intended to accelerate the development of treatments for serious conditions with limited existing therapies.

• The FDA Fast Track designation allows for more frequent communication with the regulatory body and can lead to a quicker review process.

• It may also open the door for rhu-pGSN to be accessed through the FDA’s Expanded Access or Compassionate Use programmes, potentially offering a treatment option to patients outside of clinical trials.

• The Fast Track status is expected to support the timely advancement of rhu-pGSN, offering hope for a new treatment option in an area with few alternatives.

BioAegis Advances rhu-pGSN in Global Phase 2b ARDS Trial

• Recombinant plasma gelsolin is based on a naturally occurring immune regulatory protein, which plays a key role in restoring immune balance without compromising the body’s defence mechanisms.

• BioAegis is currently advancing a global Phase 2b trial involving 600 patients to assess the safety and efficacy of rhu-pGSN in individuals with moderate to severe ARDS (NCT05947955).

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!